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We have recently shown that the novel neuropeptide cal-
citonin gene-related peptide, CGRP, is a potent vasodila-
tor. In this paper we report a detailed study of the effects 
of CGRP in human skin . CGRP induces a clearly defined, 
long-lasting erythema. We have measured the effect ofCGRP 
on blood flow in human skin using a laser Doppler tech-
nique and have demonstrated increased local blood flow 
that persists for a number of hours . We com pared the re-
sponse of CGRP with other known vasodilators [hista-
mine, prostaglandin (PG) E 2 , PGI2 , substance P, and vaso-
active intestinal peptide (VIP)] in the skin, and in all subj ects 
the erythema induced by CGRP was more persistent than 
that induced by the other mediators tes ted. Except at high 
C alcitonin gene-related peptide (CGRP) is a 37 amino acid peptide which is predicted to occur as a result of alternative processing of mRNA from the calci-tonin gene [1,2] . The calcitonin-secreting cells of the thyroid gland are derived embryonically from the 
neural crest and although calcitonin is the major product, it has 
been possible to isolate and characterize a human CGRP from 
thyroid tissue taken from patients with n1.edullary thyroid ca r-
cinoma [3] . This human CGRP consists of37 amino acid residues 
but differs at 4 amino acid sites from the previously reported 
predicted structure of rat CGRP [1] . Immunocytochemical studies 
in the rat have revealed the distribution of immunoreactive CGRP 
in the central and peripheral nervous systems [1]. In the periphery 
immunoreactive CGRP was found in thin beaded nerve fibers 
that were associated with the smooth muscle of blood vessels [lJ . 
We have found that both natural human CGRP and synthetic rat 
CGRP increase microvascular blood flow in rabbit skin, measured 
with a xenon clearance technique [4]. By directly visualizing the 
microvascular bed of the hamster cheek pouch we found that 
CGRP acts on arterioles. In human skin intradermal injection of 
low doses ofCGRP induces only local erythema, unlike the triple 
response of skin to agents such as histamine [4] . It has been 
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doses the local vasodilatation induced by CGRP was not 
associated with a wheal and flare as seen with histamine, 
substance P, and VIP. CGRP is an extremely potent vaso-
dilator and if released into the circulation, or locall y from 
peripheral nerve endings, it could have a role in the reg-
ulation of blood flow in both physiologic and pathologic 
conditions; CGRP may be the endogenous m ediator of the 
flare in the triple response. A deficiency in CGRP secretion 
or action could be an important component of peripheral 
vascular disease. Some flushin g reactions (e.g., those as-
sociated with medullary thyroid carcinoma) may result from 
circulating CGRP.) Invest Dermato/ 87:533-536, 1986 
sugges ted that the flushing of the skin which is observed in some 
patients with medullary thyroid carcinoma [5] cou ld be due to 
circulating CGRP [4]. More recently, immunoreactive CGRP has 
been detected in the plasma ofnorm31 individuals [6]. The potency 
ofCGRP in inducing erythema and its locali zation in perivascular 
nerves suggest that CGRP could have an important regulatory 
role in the con trol of blood fl ow in humans. 
In this study we have examined the effect of CGRP in human 
skin and report that CGRP has potent and persistent effects in 
stimulating local blood flow . We have compared the effect of 
CGRP in human skin with that of other known vasodilators and 
give ev idence to suggest that CGRP is one of the most potent 
and persistent vasodilators yet discovered. 
SUBJECTS AND METHODS 
Pep tides were purified by high-perfo rm ance liquid chromatog-
raphy (HPLC). Human CGRP (Sandoz) was eluted from a Waters 
J-L Bondapak C18 semipreparative column with a gradient of 0-40% 
n-propanol in 5% acetic acid in water. Substance P (Sigma) and 
vasoactive intestinal peptide (VIP) (Sigma) were eluted from the 
same column with a gradient of10-40% n-propanol in 5% acetic 
acid in water. Elution positions were confirmed by fast atom 
bombardment mass spectrometry and the peptides were quan-
titated by amino acid analysis. 
Experiments were carried out on health y volunteers using a 
total of 9 individuals (6 male and 3 fem ale, aged 21-40 years). 
The subjects gave informed consent and ethi cal approval was 
obtained. 
The test substances were prepared in 0.9% sterile pyrogen-free 
saline (saline) and injected in 50 J-LI volumes at predetermined sites 
into the volar surface of the forearm. C hanges in blood flow were 
recorded in 4 volunteers usin g a Perimed II laser Doppler flow 
meter [7]. The probe was secured in a holder 0 11 the arm for each 
reading. Readings (each taken continuously for 2 min) were taken 
at 3 sites on the forearm, just before and 10 min , 1 h, 2 h, 3 h, 
and 4 h after intraderm al injection. One site received 10 pmol 
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CGRP in sa line, the second site sa line only, and the third site was 
not injected. Results were recorded as mean % flux val ue (number 
of red blood cells moving in the volume measured by the path 
of the laser beam, 1-2 cu mm x mean cell velocity). 
CGRP (1-100 pmol) was compared w ith 5 other established 
vasod ila tors: VIP (10 pmol), substance P (10 pmol), prostaglandin 
(PG)E2' (10 pmol), PGI2, (10 pmol), and histamine (500 pmol) 
in 4 individuals. T he effect of loca l and system ic HI antihistamines 
on CG RP-indu ced erythema was exa mined by injectin g chlor-
pheniramine (Piriton, 1 J.L g) intradermal ly with CGRP (10 pmol) 
and hi stamine (500 pmol) in 3 individuals or by ad ministering 
terfenad ine (Tri ludan, 60 m g p.o . in 4 indi viduals) or chlo rphen-
iramine (Piriton 4-8 mg p.o. in 3 individuals) 2-3 h before in-
tradermal injection of CGRP (1-10 pmol) and histamine (500 
pmo l). Res ponses obtained in the presence of the antihistamines 
were compared with control responses o btained by injecting hi s-
tamine and CGRP at alternate sites on the sa me forearm in the 
case of loca l anti hi stamine, o r by obta ining responses to CGR P 
and hi sta mine on the other forearm 24 h before ad ministration 
of systemic antihistam ine. In 1 individual (TJW) the stability of 
the vasodil ator activity of CGRP was tested in autologous plasma 
and blood . Periphera l venous blood was co ll ected into heparin 
(10 units / ml). The GH.P (800 pmol/m l) was incubated for 1 h 
at 37°C in plasma, blood, or sa line. The samples were centrifuged 
and supernatants diluted 4-fold in sa line before intradermal in-
j ection of 50 J.LI in'to the forea rm. Each test sample was compared 
with a control injecti on where CGRP had been added to the 
plasma , blood, or sa line after incubation . 
The area of the res ponses was measured by placing a clear plastic 
sheet over the skin and tracing the edges of the wheal and ery-
thema at 10 min , 1 h , 2 h, 3 h, and 4 h after injection. All results 
are expressed as area (sq mm) and ca lculated by use of an Apple 
digitizer board attached to an Apple li e computer. The responses 
were usually photographed. 
RESULTS 
Fig 1 shows that CGRP increased blood flow, assessed using a 
laser Doppler flow meter. Ten minutes after injection , the saline-
injected site exhibited a raised blood flow , but this returned to 
basal values by 1 h . By this time, clearly defined local reddenjng 
(141 ± 20 sq mm, mean ± SE) was observed at sites injected 
with CGRP in all 4 individuals and blood flow was high. Blood 
flow decreased from 1 h, a decrease that correlated with a grad ual 
return to normal skin color of the erythematous area. The re-
sponses of human skin to certain inflammatory mediators is well 
documented: histamine induces the classical triple response (wheal, 
loca l reddenin g, and surrounding fl are) [8] which is also observed 
with substan ce P [9] and VIP [10], while PGE2 and PGh are potent 
in inducing loca l reddenin g [11 ,12]. In the results shown in Fig 
2 histamine, substance P, VIP, and PGE2 (in 1 individual) induced 
whea l and flare responses which had faded by 1 h after injection . 
Prostagland in E2 in the other 3 volunteers and PGI2 in all subjects 
caused only local reddening. The loca l reddening response to PGh 
faded by 1 h and the response to PGE2 disappeared by 3 h. The 
CGRP (1 and 10 pmol), in every individual, induced local red-
denin g which appeared slower in onset than that induced by PGE2 
or PGI2, because it spread slowly in the first hour as indicated by 
the increasing area (see Fig 2b) . The color of the skin was bright 
pink 1-2 h afier injection; then the response slowly faded and the 
area of erythema became smaller until it had disappeared in most 
subj ects by 3 h (1 pmol) or 5-6 h (10 pmol). However a higher 
dose of CGRP (100 pmol) did initially induce a wheal and flare 
followed by persistent local reddening. The loca l reddening in-
du ced by CGRP was similar to the persistent local reddening of 
skin to VIP . T his response to VIP consisted of a small area of 
erythema wh ich became evident as the wheal and flare to VIP 
subsided. As shown in Fig 2, the persistent erythematous response 
to VIP was smaller than that due to CGRP and faded more quickly 
in each individual. The persis tent local reddening by VIP was not 
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Figure 1. Local increased blood flow after intradermal injection of CGRP. 
Blood flow was measured at 3 sites on the volar surface of the same 
forearm in 4 individuals. Solid circle, sites that received intradermal CGRP 
(10 pmol/SO J.Ll) ; so lid square, sites that received intrade rmal sa line (50 J.Ll) ; 
ope" square, llninjected sites . B lood fl ow was measured before and at the 
times indica ted after injections. Results are expressed as mean ± SEM, 
n = 4. 
reported in a previous study of the response of human skin to 
VIP [10] . The CGRP induced a similar persistent local reddening 
whcn injected into skin after its incubation in vitro in autologous 
blood and plasma for 1 h at 37°C. This suggests either that CGRP 
is stable in blood, or that during incubation a similarly potent 
metabolite is formed; the finding is supported by our studies in 
the rabbit [13]. 
Thc efficacy of HI antihistamines was tested by their effect on 
the histamine-induced triplc response. As prcviously reported 
[14], H I antihistamine's had little effect on the histaminc-induccd 
wheal but caused an almost total suppression of the histamine-
induced flare when administered either locally, (chlorphenira-
mine, 10 min: 96.0 ± 2.0% reduction in area; mcan ± SEM, 
n = 3) or systcmica lly , (Terfenadine, 10 min: 91.3 ± 8.0% re-
duction, n = 4). Interestingly, the histamine-induced local red-
dening was abolished by local antihistamines but unaffected by 
systemic antihistamines. Local chlorpheniramine had little initial 
effect on CGRP-induced local reddening (10 min: 14.3 ± 2.4% 
reduction, n = 3) but, by 2 h a reduction in thc intensity oflocal 
reddening was apparent. By 3 h after injection this inhibition was 
more obvious and associated with a reduction in the area of local 
reddening (56.7 ± 21.3% reduction). Another antihistamine 
(promethazine hydrochloride, Phenergan, 1 J.Lg) had a similar 
inhibitory cffect when given locally. In contrast, thc persistence 
of the CGRP-induced local reddening was unaffected by systemic 
terfenadine up to 4 h after injcction (4 h: 1.7 ± 18.0% difference, 
n = 4) . Systcmic administration of chlorpheniramine, similarly 
had no effect on CGRP-induccd local reddening. It is unlikcly 
that the inhibitory effects oflocal antihistamines were due to local 
anesthetic effects as lignocaine hydrochloride (Xylocaine, 0.02%) 
did not affect the CGRP-induced local reddcning. 
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Figure 2. Skin responses after intradermal injections of vasodilators. fI , 
Immediate wheal and flare. The wheal (opell coil/mIlS) and flare (shaded 
co /umll s) responses to intradermal inj ection of histamine (HA, 500 pmol) 
substance P (SP, 10 pmol), vasoactive intes tinal peptide (VIP, 10 pmol). 
and PCE2 (10 pmol) are shown. Responses were calculated as area (sq 
rnm) and measured 10 min after injection . They are expressed as mean 
± SEM . n = 4, except for PGE2 where resul ts are fro m 1 volun teer. 
The other 3 volunteers exhibi ted only loca l reddening in response to PGE2. 
No wheal and fl are was seen after injection of CCRP (10 pmoD . PCh 
(10 pmol) or sa line (SAL) in any volunteers. b, Local reddenil~g. The area 
(sq mm) and duration of erythema in response to CGRP (circle, 10 pmol), 
solid sg'ltlre, PGE2 (10 pl11ol), PGI2 (opell sql/are, 10 pmol), and VIP (Iriml,!!le, 
10 pmol) is shown. r~csponses arc expresscd as mcan ± SE~ , n = 4, 
except for *, PGEz 10 min reading where n = 3. At 10 min I"volunteer 
responded to PGE2 and all volunteers responded to VIP with a wheal and 
flare (see a) ; it was not possible to accurately mcasure loca l reddening in 
the presence of a wheal and flare. 
D[SCUSSION 
T hese observat ions support ou r previous guantitative studies in 
animals and preliminary studies in humans [4] w hich showed that 
CGRP is a vasodilator. In this paper we have shown by visual 
observation and using laser Qoppler blood flow measurements 
that intraderma lly inj ected CGRP has potent local vasodilator 
acti vity in humans which exceeds , in duration of action, that of 
any vasodilator yet tested. T he characteristics of other potent 
vasodilators , PGEz, PGI2 , substa nce P, VIP, and histamine, were 
compared w ith those of CGRP. At the doses used, responses 
were characterist ica ll y different, The PGs induced np inly loca l 
erythema, ;'ast in o nset, and pers istin g fo r no longer than 2-3 h . 
Su bstance P induced loca l erythem a and a whea l and fl are which 
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had faded by 1 h . VIP induced a similar initia l response to that 
of substance P, but with a loca l erythem a persisting for 3 h. In 
con trast, CGRP induced on ly intense local erythema, slow in 
onset but very persi stent, up to 10-12 h duration at high doses 
[41· . 
We have suggested that CGRP may be the endogenous vaso-
di lator released fro m the endings of branches of afferent nerves 
in the skin , mediating the axon reflex flare that surroun ds the 
loca l response to inflammatory stimuli [4]. T his is supported by 
the recent finding of immunoreactive CGRP in cutaneous nerves 
associated w ith blood vessels in humans (Dr SpringaU and Pro-
fessor Polak , personal communica tion) . However, immunoreac-
tive substance P and VIP have also been detected in human skin 
[1 5] and these substances have been claimed to be the endogenous 
med iators of th e fl are reaction [1 0, 14,16]. At present, the evidence 
for and aga inst any of these ca ndidates is circumstantial; never-
theless substance P and VIP themselves induce a fl are, probably 
by releasing histamine w hich stimulates pain receptors and trig-
gers the axon refl ex. If either of these peptides is the endogenous 
m ediator, it is diffi cult to see how the area of fl are wouJd be 
limited-release of histam ine in the area surroundin g the 'ini tia l 
stimulus inducing a secondary axon reflex, and so on-unless 
other mechanisms exist to lin1it the flare area. T hus CGRP is a 
better cand idate as the mediator of the flare because it di lates onl y 
the arterioles to w hich it is exposed, without itself triggering an 
axon reflex fl are. On the other hand, the flare reaction is fast in 
onset and can be (dependin g on the intensity of the inflammatory 
stimulus) of short duration. From th is point of v iew CGRP is 
apparently not a good candidate. However, the slow onset of 
responses to intradermall y injected CGRP ma y be because it is a 
relatively large m olecule (when compared to released histamine) 
and m ay take time to diffuse to superficial mi crovessels . Our 
previous experim ents in rabbit 1'131 together w ith the res ult of 
the present experiment in humans sugges t that the vasodi lator 
activity of CGRP is stable in plas m a, and therefore presum ably 
in extravascul ar tissue fluid . T his m ay part.1 y exp lain the long 
duration of action of in'traderma ll y injected CGRP. [n contrast, 
CG RP released from cutaneous nerve endin gs may be metabo-
li zed ncar its site of release (e.g., b y enzy mes on arterio les) or 
there m ay be a reuptake mechanism in nerves .. Thus, CGRP 
released at low levels may ca use a transient flare, whereas high 
levels rel eased by an intense inflam m atory stimu lus may induce 
a persistent fl are. 
T he inhibitory effect of loca l H, antih istamines on the persis-
tence of loca l ery thema induced by CGRP was un expected. If 
CGRP, at the doses used , releases histamine, one wou ld expect 
a w hea l and flare reaction, w hich was not seen with CG RP at 
these concentrations . Further, o ral H, antihistamines suppressed 
res ponses to histam ine itself, but had no effect on erythem a in-
duced by CGRP. Hence, the phenomen on may represent an ac-
tivity of loca l antihistamines independent of hista mine receptor 
antagonism , but apparentl y not associated with loca l anesthetic 
activity of antihistamines (as li gnoca ine did not suppress the re-
sponse to CGRP). T he paradoxica l o bservation Illa y relate to the 
effectiveness o flo call y appli ed anti hista mines (w hen applied ea rly) 
.in suppressing certain local allergic reactions in the ski n . 
Locall y released CGRP m ay be in volved in the ph ysiologic 
contro l of tissu e blood fl ow and a defici~n cy in release or action 
may be an important contributory fac tor in peripheral vascular 
diseases. [n some patients w ith Rayna ud 's phenomenon or dia-
betic polyneuropath y, electrica l transcutaneous nerve stimulation 
induces vasodilation and relief from ischemic pain. It has been 
suggested that the release of an endogenous vasodilator is partly 
responsible for the beneficial effects [17]. Transcutaneous nerve 
stimulation has been associated with a rise in plasma VIP in these 
patients and normal indi viduals [18]. altho ugh further studies r 19] 
have suggested tlpt this endogenous vasodi.1ato r is not V[ P nor 
any other known substance. It is possible that this unidentified 
vasodilato r is CGRP, w hich we show here to retai n its vasodilator 
~ctivity in plasm a. T hus, exogenous CGRP, or vasodilator 3n-
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alogues, should be considered as a possib le therapeuti c agent in 
peripheral vascular diseases. We demonstrate here that the un-
stable PG I2 induces a ve ry acute vasodi lator response il1 the sk in 
w hen compared w ith the response to CGRP, and yet PG I2 has 
been reportcd to have long-term beneficial effects in periph era l 
ischemic diseases [20,21] . In support of the loca l effects we have 
demonstrated, intravenous CGRP has been shown to lower sys-
temic arterial blood pressure by reducing peripheral res istance 
[22]. 
Recen tly a rad ioimmunoassay for CG RP has been developed 
[6'1. Levels of immunoreactive CGRP in normal plas ma have been 
reported, but it is not clea r w hether this refl ects the level of the 
intact, biologicall y active molecu le. A second hum an calci-
tonin/CGRP. gene has beel) described that encodes ano ther CGRP 
[23]. This second CGRP differs in structure at 3 amino acid s it~s 
from the CGRP described and used in these experim ents. H ow-
ever, preliminary resuJts suggest that bo th of th ese forms of CGRP 
have sim ilar potencies as vasodi lators 124]. As CGRP has been 
extracted from medulJary thyroid ca rci no ma tissue, and elevated 
levels of immunoreactive CGR P have been detected in patients 
w ith such tum ors [5]. it is possible that flu shing reactions seen in 
these individua ls (and possib ly those affected w ith other tum ors) 
may resu lt from hig l; circul atin g CGRP level s. ' 
. We consider that the stud y of the roles ofCGRP in ph ysio logy 
and pathology, and its possible use as a th erapeutic agent, may 
prove to be fruitfu l areas for future resea rch. 
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